Abstract:Abstract Microvascular invasion (MVI) is presently evaluated as a high-risk factor to be directly relative to postoperative prognosis of hepatocellular carcinoma (HCC). Up to now, diagnosis of MVI mainly depends on the postoperative pathological analyses with H&E staining assay, based on numbers and distribution characteristics of MVI to classify the risk levels of MVI. However, such pathological analyses lack the specificity to discriminate MVI in HCC specimens, especially in complicated pathological tissues. In addition, the efficiency to precisely define stages of MVI is not satisfied. Thus, any biomarker for both conforming diagnosis of MVI and staging its levels will efficiently and effectively promote the prediction of early postoperative recurrence and metastasis for HCC. Through bioinformatics analysis and clinical sample verification, we discovered that Stathmin 1 (STMN1) gene was significantly up-regulated at the locations of MVI. Combining STMN1 immunostaining with classic H&E staining assays, we established a new protocol for MVI pathological diagnosis. Next, we found that the degrees of MVI risk could be graded according to expression levels of STMN1 for prognosis prediction on recurrence rates and overall survival in early HCC patients. STMN1 affected epithelial-mesenchymal transformation (EMT) of HCC cells by regulating the dynamic balance of microtubules through signaling of “STMN1-Microtubule-EMT” axis. Inhibition of STMN1 expression in HCC cells reduced their lung metastatic ability in recipients of mouse model, suggesting that STMN1 also could be a potential therapeutic target for inhibiting HCC metastasis. Therefore, we conclude that STMN1 has potentials for clinical applications as a biomarker for both pathological diagnosis and prognostic prediction, as well as a therapeutic target for HCC.

Stathmin-dependent Molecular Targeting Therapy for Malignant Tumor: the Latest 5 Years’ Discoveries and Developments

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Overexpression of Stathmin Promotes Metastasis and Growth of Malignant Solid Tumors: A Systemic Review and Meta-Analysis

Up-regulated Expression of Stathmin May Be Associated with Hepatocarcinogenesis.

Stathmin Overexpression is Associated with Growth, Invasion and Metastasis of Lung Adenocarcinoma.

Stathmin Destabilizing Microtubule Dynamics Promotes Malignant Potential in Cancer Cells by Epithelial-Mesenchymal Transition.

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Stathmin Guides Personalized Therapy in Oral Squamous Cell Carcinoma.

Research status of anti-tumor targted drugs

Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer

Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges

The effects of stathmin on cell proliferation and tumor-related genes expressions in HCCLM3 cells

Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma

Prognostic Role of High Stathmin 1 Expression in Patients with Solid Tumors: Evidence from a Meta-Analysis.

Stathmin Decreases Cholangiocarcinoma Cell Line Sensitivity to Staurosporine-Triggered Apoptosis Via the Induction of ERK and Akt Signaling

Research progress of small molecule inhibitors targeting PI3K-Akt-mTOR pathway

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives

Targeting the lung tumour stroma: harnessing nanoparticles for effective therapeutic interventions

Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges and Opportunities

Changes in Therapy for Solid Tumors: Potential for Overcoming Drug Resistance In Vivo with Molecular Targeting Agents